Background: Heart failure with reduced ejection fraction (HFrEF) is a leading cause of cardiovascular mortality and morbidity worldwide. Optimized pharmacological therapy — comprising the four pillars of neurohormonal blockade (ACE inhibitors/ARBs, beta-blockers, MRA, SGLT2i) — h...
Open access
Research Article10.9734/ca/2026/v15i2545
Background: Heart failure with reduced ejection fraction (HFrEF) represents a growing global public health burden, particularly in low- and middle-income countries where cardiovascular risk factors are prevalent and undercontrolled. Data from North Africa and Morocco remain scarc...
Open access
Research Article10.9734/ca/2026/v15i2542
Background: The etiological distribution of heart failure with reduced ejection fraction (HFrEF) varies significantly across regions, reflecting differences in cardiovascular risk factor prevalence, genetic predisposition, and healthcare access. Data from North African military p...
Open access
Research Article10.9734/ca/2026/v15i2543
Aims: This study aimed to describe the epidemiological, clinical and angiographic characteristics of patients aged under 45 years who were hospitalised for myocardial infarction and to highlight the characteristics of MI in young people compared with older people. Study Design: A...
Open access
Research Article10.9734/ca/2026/v15i3551